Gout

A post-hoc analysis evaluated pooled data from 4 trials of pegloticase.

Heat therapy often worsened symptoms in a randomized controlled trial.

However, gout flare states of patient acceptable symptom state, low disease activity, or not achieving either were not associated with EQ-5D-3L or HAQ.

Less than half of rheumatologists self-reported adhering to febuxostat and allopurinol dosing recommendations.

The exploratory MIRROR trial found pegloticase with methotrexate improved clinical assessment and quality of life outcomes in uncontrolled gout.

A study found the association between sedentary behavior and gout remained strong even when adjusting for physical activity.

These findings, from an observational study, should be confirmed in a randomized, controlled trial.

CDC, NIH, and AMA recommend PEMs to be at a 6th-to-8th-grade reading level, while assessed materials were readable at high school or higher levels.

At the highest dose levels, mean plasma urate levels remained below 6.0 mg/dL for up to 12 weeks.

Lowering serum urate level to less than 6 mg/dL was not linked to an elevated risk of severe or end-stage kidney disease progression in patients with gout.

Clinically meaningful increases in patient-reported outcomes were identified after 3 doses of SEL-212 and strengthened after 3 additional doses.

The Urate-Lowering Therapy to Acute Treatment Ratio (ULTrA) was linked to fewer gout-related hospital admissions.

Infusion reaction rates and serum level lowering were similar between 120-minute and 60-minute infusion cohorts in the phase 4 AGILE study.

IL-18 levels were consistently lower across participants with different SARDs, remission status, and COVID-19 disease characteristics.

People that reported only some or none of their flares had almost twice the rate of gout flares in the last year than those reporting all of their flares.

SGLT-2 inhibitors had more protective effects than GLP-1 receptor agonists or DPP-4 inhibitors in this population.

The rheumatology month in review emphasizes new data on secukinumab, gout clinical decision making, and addressing sleep issues in fibromyalgia.

The treatment did seem to blunt the glycemic response and influence some inflammatory cytokines.

Adherence to a preventative, favorable lifestyle significantly reduced CVD risk in participants with high and low genetic risk.

The analysis of NHANES data revealed an inverse association between dietary vitamin C intake and gout risk.

A comprehensive model of clinical and radiomic features was more accurate in distinguishing flares than either model alone.

Remission according to the simplified definition correlated with the 2016 preliminary gout remission definition and GIS score improvements.

Compared with participants who gained weight or who weight remained stable, the risk of developing gout fell with increased weight loss over 1 year.

This clinical quiz, our last in a series of 4, focuses on recommendations for special populations and long-term management from the 2020 ACR gout guidelines.

Higher Life’s Essential 8 score was associated with higher CVH scores in US adults.

Younger people and people without European origin were less likely to adhere to urate-lowering therapy.

There were no differences in the treatment effect of ertugliflozin on gout-related outcomes in subgroups based on eric acid quintile or other baseline characteristics.

The increase will largely be driven by population growth and aging.

Patients also experienced a substantial decrease in systolic blood pressure and diastolic blood pressure.

This clinical quiz, our third in a series of 4, focuses on recommendations for lifestyle and comorbidity management from the 2020 ACR guidelines.